- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Schering-Plough drugs may pay off before Merck loses patents
National report - The purchase of Schering-Plough for 41.1 billion in cash and stock has given Merck a dozen experimental drugs that are nearing marketing approval in the U.S., which may pay off before Merck loses patents on medicines with $8 billion in annual sales, Bloomberg.com reports.
National report
- The purchase of Schering-Plough for 41.1 billion in cash and stock has given Merck a dozen experimental drugs that are nearing marketing approval in the U.S., which may pay off before Merck loses patents on medicines with $8 billion in annual sales, Bloomberg.com reports.
Merck will now have new products for cancer, immune diseases and psychiatric disorders, as well as full revenue control from the cholesterol pills Zetia and Vytorin, which Merck shares with Schering-Plough, according to Bloomberg.com.
In addition, though Merck&38217s asthma drug Singulair will face generic competition by 2012, Schering-Plough has said it plans to launch seven new drugs, each with more than $1 billion in peak annual sales, Bloomberg.com reports.
